Dapmicin (Daptomycin) Injection

Description

Description

This page contains brief details about the drug daptomycin, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Daptomycin received its initial approval from the U.S. Food and Drug Administration (FDA) on September 1, 2003. It was first approved under the brand name Cubicin

Mechanism of Action of Daptomycin

Daptomycin’s mechanism of action involves disrupting the bacterial cell membrane. It binds to the bacterial cell surface, leading to rapid depolarization of the cell membrane, resulting in the leakage of cellular contents and ultimately causing bacterial cell death. By targeting the cell membrane, this medication is effective against many gram-positive bacteria, including MRSA and VRE, and is less likely to promote rapid resistance development.

Uses of Daptomycin

Daptomycin treats complicated skin and skin structure infections (cSSSI) and bloodstream infections caused by certain gram-positive bacteria, including vancomycin-resistant enterococcus (MRSA) and methicillin-resistant staphylococcus VRE.

Daptomycin Dosage available

Daptomycin is administered intravenously (IV) by a healthcare professional. The lyophilized powder is reconstituted with sterile water to prepare the solution for IV infusion. The recommended dosage and infusion rate vary based on the type and severity of the infection, as well as the patient’s weight and kidney function. This medication is usually given once daily.